BPC-157 + TB-500 Healing Combination Protocol
Research protocol for combining BPC-157 and TB-500 (Thymosin Beta-4) for synergistic tissue healing research, covering dosing rationale, administration timing, and the complementary mechanisms of these two healing peptides.
Materials Needed
- BPC-157 — reconstituted
- TB-500 (Thymosin Beta-4) — reconstituted
- Insulin syringes (separate syringe for each peptide)
- Alcohol swabs
- Research log
Dosing Calculator
Calculate the injection volume needed for your target dose.
Result:
Injection Volume
0.100 mL
Syringe Units (U-100)
10.0 units
Doses Per Vial
20
Concentration: 2500 mcg/mL (2.50 mg/mL)
Understand the Complementary Mechanisms
BPC-157 and TB-500 promote tissue healing through distinct but complementary pathways. BPC-157 acts primarily through upregulation of growth factor receptors (VEGF, FGF, EGF), nitric oxide modulation, and the FAK-paxillin pathway. TB-500 promotes healing through upregulation of actin polymerization, cell migration, and anti-inflammatory activity via NF-κB modulation. Together, they address both vascular repair (BPC-157) and cellular migration/structural repair (TB-500).
Tips
- • Review the BPC-157 and TB-500 monographs for complete mechanism details
- • The combination is widely studied in preclinical tissue repair models
Calculate Individual Doses
Typical research doses from the literature: BPC-157 at 200-500 mcg (commonly 250 mcg), TB-500 at 2-5 mg (commonly 2.5 mg during loading, then 1-2 mg for maintenance). Note that TB-500 doses are significantly larger than BPC-157. Calculate injection volumes using the Dosing Calculation Protocol.
Do not mix the two peptides in the same syringe
Tips
- • BPC-157 is dosed in micrograms (mcg), while TB-500 is typically dosed in milligrams (mg)
- • Use separate syringes for each peptide
Site-Specific vs. Systemic Administration
Research literature describes two approaches: site-specific injection (subcutaneous injection near the area of interest) and systemic injection (standard abdominal subcutaneous injection). BPC-157 research often uses site-specific injection based on studies showing enhanced local effects, while TB-500 is typically administered systemically due to its mechanism involving systemic upregulation of actin.
Tips
- • For localized research targets, BPC-157 is often injected as close to the area as safely possible
- • TB-500 can be administered at any standard subcutaneous site
Administer BPC-157
Following the Subcutaneous Injection Technique Protocol, administer BPC-157 at your chosen site. If using site-specific administration, inject subcutaneously as close to the target area as possible. Record the time, dose, and site.
Estimated time: 2 minutes
Administer TB-500
Using a fresh syringe, administer TB-500 subcutaneously. TB-500 can be administered at the same session as BPC-157 or at a different time. Some protocols separate the two by 8-12 hours (e.g., BPC-157 in the morning, TB-500 in the evening).
Estimated time: 2 minutes
Tips
- • If administering at the same time, use injection sites at least 2 inches apart
Loading and Maintenance Phases
TB-500 protocols in the literature commonly include a loading phase (higher dose for 4-6 weeks) followed by a maintenance phase (reduced dose for 4-8 weeks). BPC-157 is typically dosed consistently without loading. A common schedule: BPC-157 250 mcg 1-2x daily throughout, TB-500 2.5 mg 2x weekly for 4 weeks, then 1.5 mg 2x weekly thereafter.
Tips
- • The loading phase for TB-500 is based on achieving tissue saturation of Thymosin Beta-4
- • BPC-157 has a shorter half-life and benefits from more frequent administration
Monitor and Document
Maintain detailed records including: daily peptide doses, injection sites and times, and any observed changes throughout the research period. Photographic documentation at consistent intervals can provide objective tracking of progress in tissue healing research.
Tips
- • Photograph under consistent lighting conditions for reliable comparison
- • Research periods typically span 8-12 weeks for comprehensive observation
Related Monographs
BPC-157
An in-depth review of Body Protection Compound-157, covering its mechanism of action, research applications in tissue repair, gut health, and neuroprotection, along with key published studies.
Read monographTB-500
A comprehensive review of TB-500, a synthetic fragment of Thymosin Beta-4, examining its role in wound healing, tissue regeneration, and inflammation research.
Read monographRelated Protocols
Cognitive Peptide Research Protocol
Research protocol for nootropic peptide compounds including Selank, Semax, and Dihexa, covering nasal and subcutaneous administration routes, cycling strategies, and cognitive assessment considerations.
Anti-Aging Peptide Research Protocol
Research protocol for longevity-focused peptide compounds including Epithalon, NAD+ precursors, MOTS-c, and GHK-Cu, covering cycling strategies, biomarker tracking, and combination approaches from published gerontological research.
Bacteriostatic Water Handling Protocol
Complete guide to proper handling, storage, and use of bacteriostatic water for peptide reconstitution, including quality verification, contamination prevention, and shelf-life management.
GHRP + GHRH Combination Protocol
Research protocol for combining growth hormone-releasing peptide (GHRP) with growth hormone-releasing hormone (GHRH) analogs to achieve synergistic GH release, including timing, dosing rationale, and monitoring considerations.